Kura Oncology, Inc (KURA)

Etorro trading 970x250
Kura Oncology, Inc (KURA) Logo

About Kura Oncology, Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Its pipeline consists of small molecule product candidates that target cancer. The company’s lead product candidates are tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications; and KO-539, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California. Address: 12730 High Bluff Drive, San Diego, CA, United States, 92130

Kura Oncology, Inc News and around…

Latest news about Kura Oncology, Inc (KURA) common stock and company :

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kura Oncology, Inc. - KURA
01 Dec, 2021 Yahoo! Finance

NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Kura Oncology, Inc. (“Kura” or the “Company”) (NASDAQ: KURA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether Kura and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On

Analysts Predict 22% Gains Ahead For IEIH
29 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Evolved US.

68 Biggest Movers From Wednesday
26 Nov, 2021 FinancialContent

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) shares gained 689.4% to settle at $78.94 on Wednesday after the company priced ...

Noteworthy Wednesday Option Activity: KURA, AMRS, TNDM
24 Nov, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Kura Oncology Inc (KURA), where a total of 3,099 contracts have traded so far, representing approximately 309,900 underlying shares. That amounts to about 58.3% of KURA's average daily trading volume over the past month of 531,610 shares..

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Kura Oncology, Inc. (KURA) Investigation
24 Nov, 2021 Yahoo! Finance

NEW YORK, NY / ACCESSWIRE / November 24, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Kura Oncology, Inc. ("Kura" or the "Company") (NASDAQ:KURA).

40 Stocks Moving In Wednesday's Mid-Day Session
24 Nov, 2021 FinancialContent

Gainers Biofrontera Inc. (NASDAQ: BFRI) shares jumped 109.5% to $5.51 after Roth Capital initiated coverage on the stock with a ...

Why Kura Oncology Stock Is Sliding Today
24 Nov, 2021 FinancialContent

A partial clinical hold for the company's experimental leukemia treatment is making investors nervous.

See Why FDA Hit Red Light On Kura's Early-Stage Leukemia Trial
24 Nov, 2021 FinancialContent

The FDA hasslapped a partial clinical holdon the early-stage program for one ofKura Oncology Inc’s(NASDAQ: ...

FDA Slams Kura Oncology With A Clinical Hold — And Investors Slam Its Stock
24 Nov, 2021 FinancialContent

The FDA placed Kura Oncology's leukemia study on partial hold Wednesday after a patient died — and the biotech stock plummeted.

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
24 Nov, 2021 FinancialContent

Gainers Ocuphire Pharma (NASDAQ:OCUP) stock rose 78.73% to $6.22 during Wednesday's pre-market session. The market ...

The Daily Biotech Pulse: Kura's Blood Cancer Drug Study Gets Partial Clinical Hold, Takeda FDA Nod, Puma Breast Cancer Treatment Gets Patent Extension
24 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Puma Biotech Announces ...

Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia
24 Nov, 2021 Yahoo! Finance

Management to host webcast and conference call today at 8:30 a.m. ETSAN DIEGO, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has placed the KOMET-001 Phase 1b study of KO-539 in patients with relapsed or refractory acute myeloid leukemia (AML) on a partial clinical hold. The parti

Kura Oncology, inc (KURA) Q3 2021 Earnings Call Transcript
05 Nov, 2021 FinancialContent

KURA earnings call for the period ending September 30, 2021.

Kura Oncology Reports Third Quarter 2021 Financial Results
04 Nov, 2021 Yahoo! Finance

– Continued enrollment in Phase 1b study of menin inhibitor KO-539 in NPM1-mutant and KMT2A-rearranged relapsed/refractory AML – – ASH presentation to highlight molecular mechanisms of activity for KO-539 and potential for synergistic activity in combination with venetoclax – – First clinical site activated in Phase 1/2 trial of tipifarnib plus alpelisib in HNSCC – – $543.4 million in cash, cash equivalents and investments provide runway into 2024 – – Management to host webcast and conference ca

The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
04 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral ...

Kura Oncology to Participate in Credit Suisse Healthcare Conference
02 Nov, 2021 Yahoo! Finance

SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Credit Suisse 30th Annual Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 3:30 p.m. ET / 12:30 p.m. PT on Tuesday, November 9, 2021. A live audio webc

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
31 Oct, 2021 FinancialContent

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly ...

Kura Oncology to Report Third Quarter 2021 Financial Results
28 Oct, 2021 Yahoo! Finance

SAN DIEGO, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2021 financial results after the close of U.S. financial markets on Thursday, November 4, 2021. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide

As Teresa Bair begins new role with Kura Oncology, she isn't cutting ties with Buffalo
19 Oct, 2021 Yahoo! Finance

Teresa Bair in early October left her position at Buffalo-based Athenex, where she spent six years as general counsel and senior VP.

Kura Oncology Appoints Teresa Bair as Chief Legal Officer
18 Oct, 2021 Yahoo! Finance

SAN DIEGO, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Teresa Bair as Chief Legal Officer and Corporate Secretary. Ms. Bair joins Kura with more than 25 years of combined in-house and law firm experience, most recently as General Counsel at Athenex. “On behalf of our board and senior leadership team, we want

Kura Oncology to Participate in Two Upcoming Investor Conferences
07 Sep, 2021 FinancialContent
PepGen Announces New Additions to Leadership Team and Board of Directors
31 Aug, 2021 FinancialContent
Jon Najarian Sees Unusual Options Activity In Lucid Motors, Kura Oncology And More
24 Aug, 2021 FinancialContent

Jon Najarian spoke on CNBC's "Options Action" about unusually high options activity in Lucid Group Inc (NASDAQ: LCID) on ...

First Week of April 2022 Options Trading For Kura Oncology
23 Aug, 2021 FinancialContent

Investors in Kura Oncology Inc (KURA) saw new options begin trading this week, for the April 2022 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
20 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
18 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

2 “Strong Buy” Stocks Trading at Rock-Bottom Prices
18 Aug, 2021 Yahoo! Finance

Buy cheap? Even in the stock market, buyers like to find a bargain. Defining a bargain, however, can be tricky. There’s a stigma that gets attached to low stock prices, based on the reality that most stocks don’t fall without a reason. And those reasons are usually rooted in some facet of poor company performance. But not always, and that’s why finding stock bargains can be tricky. There are plenty of low-priced equities out there with sound fundamentals and solid future prospects, and these opt

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
17 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Monday
16 Aug, 2021 FinancialContent

On Monday morning, 207 companies hit new 52-week lows. Intriguing Points: The largest company in terms of market cap ...

Stocks That Hit 52-Week Lows On Friday
13 Aug, 2021 FinancialContent

Friday morning, 94 companies reached new 52-week lows. Significant Points: Wix.com (NASDAQ:WIX) is the ...

Kura Oncology, Inc (KURA) is a NASDAQ Common Stock listed in , ,

970x250